Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).
The most common cause of blindness in the elderly is age-related macular degeneration, or AMD. In cases of “wet AMD,” abnormal blood vessels grow behind the retina and leak blood and fluid, resulting in rapid sight loss. …
… which is marketed globally for the treatment of chronic moderate-to-severe plaque psoriasis; LUCENTIS, which is marketed globally for the treatment of neovascular (wet) age-related macular degeneration; and CIMZIA, which is approved …
Macular degeneration, the leading cause of blindness in Britain, causes loss of central vision. Although the National Institute for Health and Clinical Excellence (Nice) has approved the drug Lucentis for use in patients aged 50 or …
June 14th, 2007 Novartis AG’s Lucentis drug against wet age-related macular degeneration (AMD) received a recommendation from the UK’s National Institute for Health and Clinical Excellence (NICE) for use on the National Health Service. …
